Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New upgrade:   Journal your trades with more detail

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Exagen Inc.

Contributing Author

Recent Articles by Exagen Inc.

Aug-04
Exagen Inc. Reports Second Quarter 2026 Financial Results XGN +37.82% GlobeNewswire
Jul-28
Exagen Inc. to Participate in Upcoming Investor Conference XGN GlobeNewswire
Jul-21
Exagen to Announce Second Quarter Financial Results on August 4, 2026 XGN GlobeNewswire
Jun-01
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus XGN +7.43% GlobeNewswire
May-11
Exagen Inc. Reports First Quarter 2026 Results XGN +34.92% GlobeNewswire
Apr-27
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 XGN GlobeNewswire
Mar-10
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results XGN GlobeNewswire
Mar-03
Exagen Inc. to Participate in Upcoming Investor Conferences XGN GlobeNewswire
Feb-24
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 XGN GlobeNewswire
Jan-11
Exagen Inc. Announces Select Preliminary 2025 Financial Results XGN GlobeNewswire
Nov-11
Exagen Inc. to Participate in Fourth Quarter Investor Conferences XGN GlobeNewswire
Nov-04
Exagen Inc. Reports Strong Q3 2025 Results XGN -8.96% GlobeNewswire
Oct-23
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence XGN GlobeNewswire
Oct-21
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 XGN GlobeNewswire
Aug-06
Exagen Inc. to Participate in Third Quarter Investor Conferences XGN GlobeNewswire
Jul-29
Exagen Inc. Reports Strong Q2 2025 Results XGN +14.34% GlobeNewswire
Jul-17
Exagen Inc. Appoints Chas McKhann to Board of Directors XGN GlobeNewswire
Jul-15
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 XGN GlobeNewswire
Jun-23
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics XGN GlobeNewswire
May-09
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares XGN -7.31% GlobeNewswire
May-08
Exagen Inc. Prices Public Offering of Common Stock XGN -9.81% GlobeNewswire
May-07
Exagen Inc. Announces Proposed Public Offering of Common Stock XGN +6.39% GlobeNewswire
May-05
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume XGN GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)